Nipaxon (Noscapine)

Noscapine acts centrally on the medullary cough centre of the brainstem. It modulates sigma‑1 receptors and other neuronal pathways, reducing the cough reflex without engaging opioid receptors, which allows cough suppression while preserving normal breathing.

The dose of Nipaxon is determined by the prescribing clinician based on the patient’s age, weight, and severity of cough. Dosage recommendations are provided in the product’s prescribing information and should be followed exactly as instructed by a qualified health professional.

Safety data for noscapine during pregnancy and lactation are limited. Health‑care providers should weigh the potential benefits against possible risks before prescribing Nipaxon to pregnant or nursing women, and use it only if clearly indicated.

To order Nipaxon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The most common alternative for cough suppression is codeine, an opioid. Unlike codeine, noscapine is non‑opioid, does not cause respiratory depression, and has a lower potential for dependence. However, codeine may be more effective for severe, painful coughs, while Nipaxon is preferred for mild to moderate dry coughs where opioid use is undesirable.

Nipaxon should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

Nipaxon is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber or the product label for optimal absorption.

Serious risks, although rare, include severe allergic reactions such as anaphylaxis, serious skin reactions like Stevens‑Johnson syndrome, and hepatic dysfunction indicated by jaundice or abnormal liver tests. Patients should seek immediate medical attention if they experience rash, swelling, difficulty breathing, or signs of liver injury.

Nipaxon should not be used by individuals with a known hypersensitivity to noscapine or any of the product’s excipients. It is also contraindicated in patients with severe hepatic impairment and should be used with caution in children under the age specified in the prescribing information.